Spruce Biosciences, INC 8-K filings

Spruce Biosciences reported Q2 2026 results, highlighting progress towards a TA-ERT BLA submission in Q4 2026, initiation of the TrAnsform study, and a $5.5 million strategic investment from patient advocacy groups.

Spruce Biosciences announced the appointment of Dr. Adrian Quartel as its new Chief Medical Officer, effective July 27, 2026.

Spruce Biosciences Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its accounting firm.

Spruce Biosciences reported Q1 2026 financial results, highlighting progress on its TA-ERT program for MPS IIIB, strengthened leadership, and a bolstered cash position extending runway into late 2027.

Spruce Biosciences ended its collaboration with Kaken for tildacerfont in Japan while reporting positive 2025 financials and progressing its lead TA-ERT program for MPS IIIB towards a Q4 2026 BLA submission.

Spruce Biosciences announced positive long-term data for its tralesinidase alfa enzyme replacement therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB), demonstrating preserved cognitive and motor outcomes.

Spruce Biosciences has secured up to $50 million in growth capital from Avenue Capital, extending its cash runway into 2027 to advance its lead therapy for Sanfillipo Syndrome Type B.

Spruce Biosciences, Inc. announced the appointment of Keli Walbert as a Class I Director and member of its Compensation Committee, effective December 11, 2025.

Spruce Biosciences announced a stock option repricing to retain key personnel and the immediate resignation of a board director.

Spruce Biosciences announced Q3 2025 financial results, a $50 million private placement, and FDA Breakthrough Therapy Designation for its TA-ERT for Sanfillipo Syndrome Type B.

Dr. Bali Muralidhar has resigned from Spruce Biosciences' Board of Directors and Compensation Committee, effective October 15, 2025.

Spruce Biosciences, Inc. announced a private placement of common stock and pre-funded warrants, raising approximately $50.0 million to fund its clinical development and pre-commercial activities.

Spruce Biosciences announced positive long-term clinical data for its Sanfilippo Syndrome Type B therapy, Tralesinidase Alfa, and initiated a Phase 2 trial for Major Depressive Disorder, alongside its second quarter 2025 financial results.

Spruce Biosciences, Inc. announced a 1-for-75 reverse stock split, effective August 4, 2025, aimed at meeting Nasdaq's minimum bid price requirement for continued listing.

Spruce Biosciences, Inc. announced that its appeal against Nasdaq delisting was accepted, allowing the company to resume trading on the Nasdaq Capital Market if it regains compliance with the minimum bid price requirement by August 5, 2025.

Spruce Biosciences, Inc. has issued a single share of Series A Preferred Stock to its Executive Chair, Michael Grey, granting significant voting power solely for a potential reverse stock split, with votes mirroring common shareholder sentiment.

Spruce Biosciences announced its first quarter 2025 financial results, highlighting the acquisition of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for Sanfilippo Syndrome Type B (MPS IIIB) and progress on other pipeline programs.

Spruce Biosciences is reducing its workforce by 55% to focus on tralesinidase alfa development and has received a delisting notice from Nasdaq due to non-compliance with minimum bid price requirements.

Spruce Biosciences announces a new corporate strategy centered around the acquisition of Tralesinidase Alfa (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB), with a BLA submission anticipated in the first half of 2026.

Spruce Biosciences filed a notification of late filing (Form 12b-25) with the SEC regarding its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

Spruce Biosciences has announced the departure of its Chief Medical Officer, Ralph William Charlton III, and the appointment of Kirk Ways as interim Chief Medical Officer, effective December 20, 2024.

Spruce Biosciences announced that its Phase 2b trial for tildacerfont in adult Congenital Adrenal Hyperplasia (CAH) did not meet its primary endpoint, leading to the discontinuation of the program.

Spruce Biosciences reported its Q3 2024 financial results and provided updates on its clinical trials, including anticipated topline data readouts in December 2024.

Spruce Biosciences has been granted a 180-day extension by Nasdaq to regain compliance with the minimum bid price rule, resulting in a transfer of its listing to the Nasdaq Capital Market.

Spruce Biosciences reported its second quarter 2024 financial results, highlighted by a new collaboration with HMNC Brain Health for a personalized MDD treatment and upcoming topline data from key CAH studies.

Spruce Biosciences has secured a backup bid to acquire Eiger BioPharmaceuticals' Avexitide assets for $34.7 million, following an auction where they were outbid.

Spruce Biosciences reports positive final results from its Phase 2 POWER trial, showing tildacerfont significantly reduced DHEAS levels and increased SHBG in women with PCOS.

Spruce Biosciences held its 2024 Annual Meeting of Stockholders, electing two Class I Directors and ratifying BDO USA, LLP as its independent auditor for the fiscal year ending December 31, 2024.

Spruce Biosciences announced its first quarter 2024 financial results and provided updates on its clinical trials for congenital adrenal hyperplasia (CAH), highlighting key data from the CAHmelia and CAHptain programs.

Spruce Biosciences has been notified by Nasdaq that it is not in compliance with the minimum bid price requirement, as its stock price has fallen below $1.00 for 30 consecutive days.